What intrigues me here are the discussions about data from the Osiris trials. I would be extraordinarily surprised if Mesoblast includes any of the data from those in the BLA for a start. It is not the Osiris product before the ODAC, it is the Mesoblast product and the data from the trials and studies Mesoblast has performed.
Why would the ODAC have an interest in any data generated by Osiris?
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-290
-
- There are more pages in this discussion • 565 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |